LY6D Identifies Persistent Stem-Like Cells Driving Pancreatic Tumorigenesis: Gut | July 2026
Introduction:
Pancreatic ductal adenocarcinoma (PDAC) develops through complex cellular heterogeneity driven by oncogenic KRAS and chronic inflammation. This study identifies LY6D as a marker of a persistent stem-like, gastric-like premalignant cell population that drives PDAC initiation, progression, and metastasis.
Why was this study needed?
- PDAC remains one of the deadliest cancers due to late diagnosis and early metastasis.
- The premalignant cell populations responsible for tumor initiation have not been clearly defined.
- Biomarkers for early detection and therapeutic intervention are urgently needed.
- Cellular heterogeneity contributes to treatment resistance and disease progression.
- Understanding early tumor evolution may uncover novel therapeutic targets.
Results:
- LY6D identified a distinct gastric-like stem-cell population that emerged early during pancreatic tumorigenesis and persisted throughout disease progression, representing a key driver of PDAC development.
- LY6D-positive cells exhibited enhanced stemness, metastatic potential, and a unique dependence on oxidative phosphorylation (OXPHOS), while genetic deletion of LY6D delayed tumor formation and reduced progression.
- High LY6D expression independently predicted poor survival in patients with PDAC, confirming its clinical relevance as both a prognostic biomarker and a potential therapeutic target.
Clinical Impact:
This study identifies LY6D as a pan-stage therapeutic target linking early premalignant transformation with advanced pancreatic cancer. Targeting the LY6D–FOSL1 signaling pathway or its associated OXPHOS metabolic dependency may offer new opportunities for early intervention, precision therapy, and prevention of metastasis.
Bottom Line:
LY6D marks a persistent stem-like gastric-cell state that fuels pancreatic cancer initiation, progression, and metastasis. As both an independent prognostic biomarker and a therapeutic target, LY6D represents a promising avenue for early detection and next-generation precision treatment in PDAC.
